{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:13Z","timestamp":1786982113493,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11882-021-01013-y","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T04:08:48Z","timestamp":1623298128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Biologic Therapies for Allergic Rhinitis and Nasal Polyposis"],"prefix":"10.1007","volume":"21","author":[{"given":"Bob","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Anterasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"issue":"5","key":"1013_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1056\/NEJMcp1412282","volume":"372","author":"LM Wheatley","year":"2015","unstructured":"Wheatley LM, Togias A. Clinical practice: allergic rhinitis. N Engl J Med. 2015;372(5):456\u201363.","journal-title":"N Engl J Med"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11882-014-0435-7","volume":"14","author":"G Scadding","year":"2014","unstructured":"Scadding G. Cytokine profiles in allergic rhinitis. Curr Allergy Asthma Rep. 2014;14:435.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1013_CR3","doi-asserted-by":"crossref","unstructured":"Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods.\u00a02012;384(1\u20132):25\u201332.","DOI":"10.1016\/j.jim.2012.06.013"},{"issue":"3","key":"1013_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1399-3038.1997.tb00168.x","volume":"8","author":"M Benson","year":"1997","unstructured":"Benson M, Strannegard IL, Wennergren G, Strannegard O. Cytokines in nasal fluids from school children with seasonal allergic rhinitis. Pediatr Allergy Immunol. 1997;8(3):143\u20139.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"1013_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/all.12090","volume":"68","author":"C Pilette","year":"2013","unstructured":"Pilette C, Jacobson MR, Ratajczak C, Detry B, Banfield G, VanSnick J, et al. Aberrant dendritic cell function conditions Th2- cell polarization in allergic rhinitis. Allergy. 2013;68(3):312\u201321.","journal-title":"Allergy."},{"key":"1013_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert P, Bruaene NV, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128:989\u201395.","journal-title":"J Allergy Clin Immunol"},{"key":"1013_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","volume":"118","author":"P Gevaert","year":"2006","unstructured":"Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133\u201341.","journal-title":"J Allergy Clin Immunol"},{"key":"1013_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2011.05.013","volume":"128","author":"GC Nicholson","year":"2011","unstructured":"Nicholson GC, Kariyawasam HH, Tan AJ, Hohfeld JM, Quinn D, Walker C, et al. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. J Allergy Clin Immunol. 2011;128:800\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1013_CR9","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2006.06.014","volume":"118","author":"S Miyahara","year":"2006","unstructured":"Miyahara S, Miyahara N, Matsubara S, Takeda K, Koya T, Gelfand EW. IL-13 is essential to the late-phase response in allergic rhinitis. J Allergy Clin Immunol. 2006;118:1110\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"1013_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaci.2012.06.034","volume":"130","author":"JL Ingram","year":"2012","unstructured":"Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130:829\u201342.","journal-title":"J Allergy Clin Immunol"},{"key":"1013_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1365-2222.2005.02301.x","volume":"35","author":"Y Wang","year":"2005","unstructured":"Wang Y, McCusker CT. Interleukin-13-dependent bronchial hyper-responsiveness following isolated airway allergen challenge in a murine model of allergic rhinitis and asthma. Clin Exp Allergy. 2005;35:1104\u201311.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"1013_CR12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","volume":"365","author":"J Corren","year":"2011","unstructured":"Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"1013_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1084\/jem.168.3.853","volume":"168","author":"DA Lebman","year":"1988","unstructured":"Lebman DA, Coffman RL. Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures. J Exp Med. 1988;168(3):853\u201362.","journal-title":"J Exp Med"},{"issue":"26","key":"1013_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455\u201366.","journal-title":"N Engl J Med"},{"issue":"10","key":"1013_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.molmed.2004.08.004","volume":"10","author":"TA Chatila","year":"2004","unstructured":"Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med. 2004;10(10):493\u20139.","journal-title":"Trends Mol Med"},{"issue":"5","key":"1013_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio R, Mullol J, Ferguson B, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379.","journal-title":"JAMA"},{"issue":"2 Suppl 1","key":"1013_CR17","first-page":"S118","volume":"64","author":"BN Swanson","year":"2015","unstructured":"Swanson BN, Mannent L, Hamilton JD, Zhang D, Tian N, Wang Y, et al. The effect of dupilumab on biomarkers in the peripheral blood and nasal secretions in the treatment of chronic sinusitis with nasal polyposis. Inflamm Res. 2015;64(2 Suppl 1):S118\u20139.","journal-title":"Inflamm Res"},{"issue":"4","key":"1013_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/all.13685","volume":"74","author":"K Jonstam","year":"2019","unstructured":"Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, et al. Dupilumab reduces local Type-2 proinflammatory biomarkers in patients with chronic sinusitis and nasal polyposis. Allergy. 2019;74(4):743\u201352.","journal-title":"Allergy."},{"issue":"10209","key":"1013_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"\u2022\u2022 Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350 Dupilumab phase 3 trials demonstrating efficacy and safety, which led to approval of dupilumab as the first biologic for the treatment of CRSwNP.","journal-title":"Lancet."},{"issue":"1","key":"1013_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013 Sep;131(1):110\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1013_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"\u2022\u2022 Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605 Omalizumab phase 3 trials demonstrating efficacy and safety for patients with CRSwNP.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1013_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/ACI.0b013e32834c3d30","volume":"11","author":"J Corren","year":"2011","unstructured":"Corren J. Anti-interleukin-5 antibody therapy in asthma and allergies. Curr Opin Allergy Clin Immunol. 2011;11(6):55\u2013570.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"71","key":"1013_CR23","first-page":"305","volume":"13","author":"J Corren","year":"2012","unstructured":"Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med. 2012;13(71):305\u201312.","journal-title":"Discov Med"},{"issue":"1","key":"1013_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000023924","volume":"116","author":"K Asakura","year":"1998","unstructured":"Asakura K, Saito H, Watanabe M, Ogasawara H, Matsui T, Kataura A. Effects of anti-IL-5 monoclonal antibody on the murine model of nasal allergy. Int Arch Allergy Immunol. 1998;116(1):49\u201352.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"1013_CR25","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.4049\/jimmunol.168.6.3017","volume":"168","author":"H Saito","year":"2002","unstructured":"Saito H, Matsumoto K, Denburg AE, Crawford L, Ellis R, Inman MD, et al. Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. J Immunol. 2002;168(6):3017\u201323.","journal-title":"J Immunol"},{"issue":"2","key":"1013_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","volume":"7","author":"SF Weinstein","year":"2019","unstructured":"\u2022 Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2019;7(2):589\u201396 Study showing that patients with CRSwNP had a larger reduction in frequency of asthma attacks compared to asthma patients without CRSwNP when treated with reslizumab.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1013_CR27","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"\u2022 Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024\u201331 Study showing decreased need for nasal surgery in patients with CRSwNP treated with mepolizumab.","journal-title":"J Allergy Clin Immunol"},{"key":"1013_CR28","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Hopkins C, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study. Poster presented at the International Congress of the European Respiratory Society, September 7-9, 2020. Abstract in European Respiratory Journal. 2020;56:4616. Mepolizumab phase 3 study demonstrating efficacy and safety for patients with CRSwNP.","DOI":"10.1183\/13993003.congress-2020.4616"},{"key":"1013_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2058738420950851","volume":"34","author":"N Lombardo","year":"2020","unstructured":"Lombardo N, Pelaia C, Ciriolo M, Della Corte M, Piazzetta G, Lobello N, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:1\u20138.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1013_CR30","doi-asserted-by":"crossref","unstructured":"\u2022 Maspero J, Harrison T, Werkstrom V, Wu Y, Gopalan G, Zangrilli J. Clinical efficacy of benralizumab in patients with severe uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIRCCO and CALIMA trials. Abstract in J Allergy Clin Immunol. 2018 1;141(2):AB12. Study showing a larger reduction of asthma exacerbations in patients with nasal polyps treated with benralizumab.","DOI":"10.1016\/j.jaci.2017.12.038"},{"key":"1013_CR31","doi-asserted-by":"crossref","unstructured":"\u2022 Harrison TW, Chanez P, Menzella F, Walter Canonica G, Louis R, Cosio BG, et al. Exacerbation reduction and early and sustained improvements in SGRQ, lung function, and symptoms of nasal polyposis with benralizumab for severe, eosinophilic asthma: phase IIIb ANDHI Trial. Poster presented at the American Thoracic Society International Conference, May 15-20, 2020. Study showing improvement in sino-nasal symptoms in patients with CRSwNP treated with benralizumab.","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4274"},{"issue":"9","key":"1013_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"1013_CR33","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/cea.12123","volume":"43","author":"M Wang","year":"2013","unstructured":"Wang M, Zhang W, Shang J, Yang J, Zhang L, Bachert C. Immunomodulatory effects of IL-23 and IL-17 in a mouse model of allergic rhinitis. Clin Exp Allergy. 2013;43(8):956\u201366.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"1013_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1398-9995.2011.02735.x","volume":"67","author":"YH Kim","year":"2012","unstructured":"Kim YH, Yang TY, Park CS, Ahn SH, Son BK, Kim JH, et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy. 2012;67(2):183\u201390.","journal-title":"Allergy."},{"issue":"6","key":"1013_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000484527","volume":"79","author":"W Song","year":"2017","unstructured":"Song W, Wang C, Zhou J, Pan S, Lin S. IL-33 expression in chronic rhinosinusitis with nasal polyps and its relationship with clinical severity. ORL J Otorhinolaryngol Relat Spec. 2017;79(6):323\u201330.","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"1013_CR36","unstructured":"Mulroy D. Anaptysbio reports top-line data from interim analysis of ECLIPSE phase 2 clinical trial of etokimab in chronic rhinosinusitis with nasal polyps. AnaptysBio Website. Accessed 2 Dec 2020."}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-021-01013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-021-01013-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-021-01013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T09:57:57Z","timestamp":1672394277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-021-01013-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1007\/s11882-021-01013-y","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"29 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author BG has the following disclosures relevant to this manuscript: speaking honoraria from GSK, Sanofi, Regeneron, and OptiNose as well as consulting fees from Regeneron and Astra-Zeneca; Research Support from Genentech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"36"}}